On 12 Nov 2026 Dexcom closed at $81.39, +22.6% this year; market cap $31.21bn, P/E 31.5.
Health Care · Health Care Equipment · NASDAQ · United States
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
| Market cap | $31.21bn |
| P/E (trailing) | 31.5 |
| EPS (TTM) | $2.58 |
| Beta | 1.44 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 29 Oct 2026 |
| Next earnings | 28 Jan 2027 |
| YTD | +22.6% |
| 1Y | +36.5% |
| 3Y | -6.1% |
| 5Y | -12.8% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $4.66bn | $836.30m | $1.08bn |
| 2024 | $4.03bn | $576.20m | $630.70m |
| 2023 | $3.62bn | $541.50m | $511.90m |
| 2022 | $2.91bn | $341.20m | $304.70m |
| 2021 | $2.45bn | $216.90m | $53.30m |
Base value $156.39 (+92.1% vs price); 1 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.